[Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
OBJECTIVE
To explore the possibility of using lymphokine activated killer (LAK) from cord blood as an adoptive immunotherapy for ovarian cancer.


METHODS
The nude mouse models with human ovarian cancer were treated with the LAK from cord blood and compared with those treated with the LAK from the pheripheral blood.


RESULTS
The LAK from the cord blood inhibited the growth of human ovarian cancer. The average size of the tumor was 6.0 mm3 23 days after the cord blood LAK treatment, with an average weight of (0.674 +/- 0.45 g).


CONCLUSIONS
Cord blood can be a source of adoptive cellular immunotherapy for the treatment of ovarian cancer.
He
Yue-dong
YD
Department of Obsterics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Peng
Zhi-lan
ZL
Liu
Shan-ling
SL
Wang
He
H
Pan
Xiao-ling
XL
D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D005312:Fetal Blood / Q000166:cytology* / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*